Reach Us +44-1904-929220
Proteomic Approaches For Profi Ling Cancer Signaling Pathways | 3648

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Proteomic approaches for profi ling cancer signaling pathways

2nd World Congress on Biomarkers & Clinical Research

Fei Ye

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

After human genome is decoded, the characterization of the proteins is the next challenging task. Unlike genomic studies where individual changes may not have functional signifi cance, protein expression is closely aligned with cellular function and activity. Th e proteomic profi ling of functionally important regulatory proteins in cancer cells may shed light on the understanding of the molecular mechanisms of cancer development and metastasis. Uncovering the underlying protein signaling network changes in cancer aids in understanding the molecular mechanism of carcinogenesis and identifi es the characteristic signaling network signatures unique for diff erent cancers and specifi c cancer subtypes. Th e identifi ed signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past several decades, several proteomic approaches have been adopted to identify some signaling proteins and to help us understand their structure, function, and clinical signifi cances in various cancers. We recently developed a powerful proteomic approach called Protein Pathway Array (PPA) analysis that allows identifying the important, but low abundance proteins and phosphoproteins in various cancers. In recent years, using proteomic approaches, we and others have identifi ed various cancer biomarkers in diagnosis, prognosis and therapeutic target identifi cation in various cancers. Th is presentation summarizes the usage of proteomics in recent years as an important technique in defi ning the proteome of cancer, which has helped in elaborate understanding of the diseases and has provided new avenues for developing better therapeutics and prognosis.
Fei Ye has completed her Ph.D at the age of 31 years from Norman Bethune University of Medical Sciences (NBUMS) in China and postdoctoral studies from Tongji Medical University in China. She is the assistant director of Molecular Pathology Division and assistant professor of Department of Pathology at Mount Sinai School of medicine. She has published more than 30 papers in reputed journals and serving as a reviewer of several repute journals including Cancer Letters and Cancer Investigation.
Relevant Topics